These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26307969)

  • 21. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.
    Verteporfin In Photodynamic Therapy Study Group
    Am J Ophthalmol; 2001 May; 131(5):541-60. PubMed ID: 11336929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.
    Parmeggiani F; Gemmati D; Costagliola C; Sebastiani A; Incorvaia C
    Pharmacogenomics; 2009 Jan; 10(1):81-95. PubMed ID: 19102718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
    Bressler NM;
    Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
    Retina; 2006; 26(9):988-93. PubMed ID: 17151484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of subfoveal choroidal neovascularization secondary to age related macular degeneration with single treatment of verteporfin photodynamic therapy: a safety and short-term outcome.
    Tayanithi P; Pisankosakul P; Laksakapuk P
    J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S78-82. PubMed ID: 16083167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study.
    Chan WM; Lai TY; Wong AL; Tong JP; Liu DT; Lam DS
    Br J Ophthalmol; 2006 Mar; 90(3):337-41. PubMed ID: 16488958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls.
    Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hara W; Yoshida T; Tokoro T; Mochizuki M
    Am J Ophthalmol; 2008 Mar; 145(3):518-526. PubMed ID: 18207125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration.
    Parmeggiani F; Gallenga CE; Costagliola C; Semeraro F; Romano MR; Dell'Omo R; Russo A; De Nadai K; Gemmati D; D'Angelo S; Bolletta E; Sorrentino FS
    Sci Rep; 2019 Feb; 9(1):2614. PubMed ID: 30796269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Verteporfin photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia: a 12-month retrospective review.
    Costagliola C; Campa C; Incorvaia C; Parmeggiani F; Menzione M; Della Corte M; Rinaldi M; Romano M; Semeraro F
    Eur J Ophthalmol; 2008; 18(6):955-9. PubMed ID: 18988168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year outcomes after photodynamic therapy in patients with age-related macular degeneration with poor baseline visual acuity.
    Potter MJ; Szabo SM
    Graefes Arch Clin Exp Ophthalmol; 2006 Aug; 244(8):1026-8. PubMed ID: 16341540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.
    Spaide RF; Sorenson J; Maranan L
    Ophthalmology; 2003 Aug; 110(8):1517-25. PubMed ID: 12917166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.
    Sickenberg M; Schmidt-Erfurth U; Miller JW; Pournaras CJ; Zografos L; Piguet B; Donati G; Laqua H; Barbazetto I; Gragoudas ES; Lane AM; Birngruber R; van den Bergh H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
    Arch Ophthalmol; 2000 Mar; 118(3):327-36. PubMed ID: 10721954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.
    Blinder KJ; Bradley S; Bressler NM; Bressler SB; Donati G; Hao Y; Ma C; Menchini U; Miller J; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Strong HA; Stur M; Su XY; Virgili G; ;
    Am J Ophthalmol; 2003 Sep; 136(3):407-18. PubMed ID: 12967792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case series outcomes at 1 week following verteporfin photodynamic therapy.
    Tan W; Beaumont PE; Chang AA
    Retina; 2003 Apr; 23(2):166-70. PubMed ID: 12707594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].
    Chen YX; Ge J; Yan M; Jin CJ; Zhang MX; Dong FT; Lu F; Zhang CF; Zhao JL
    Zhonghua Yan Ke Za Zhi; 2007 Mar; 43(3):198-205. PubMed ID: 17605900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
    Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
    Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Japanese Age-Related Macular Degeneration Tial (JAT) Study Group
    Am J Ophthalmol; 2003 Dec; 136(6):1049-61. PubMed ID: 14644215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.